Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): A single-centre retrospective observational study in the UK and a review of the literature

Mediterranean Journal of Rheumatology

Sneha Varughese¹  Stephen Jones¹  Chandini Rao¹  Andrew Jeffries¹  Helen Veevers¹  Hanadi Sari-Kouzel¹  Madenidou Anastasia-Vasiliki¹ 

[1] Rheumatology Department, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom,;

关键词: arthritis;    biologics;    biosimilars;    etanercept;    sb4;   

DOI  :  10.31138/mjr.30.1.69

来源: DOAJ

【 授权许可】

Unknown